Form 4: Mersana Therapeutics Director Alleva Receives Stock Options in Lieu of Cash Retainer

Director Lawrence M. Alleva of Mersana Therapeutics, Inc. received 12,521 stock options on January 2, 2025, in lieu of a cash retainer for director services.

Summary

• Lawrence M. Alleva, a director at Mersana Therapeutics, Inc., was granted 12,521 stock options on January 2, 2025.
• The options were granted in lieu of a $14,750 cash retainer for director services for the quarter ended December 31, 2024.
• The stock options have an exercise price of $1.40 and expire on January 1, 2035.
• The options were granted pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy, as amended.
• The options are fully vested as of the date of grant.

Sentiment

Score: 6

Explanation: Neutral sentiment. This is a routine transaction related to director compensation. The director accepting stock options in lieu of cash could be seen as a slightly positive signal.

Positives

• The director's decision to receive stock options instead of cash may signal confidence in the company's future performance.

Industry Context

Director compensation packages often include stock options to align the interests of directors with those of shareholders. This is a common practice in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a typical component of director compensation in publicly traded companies, especially in the biotech sector.
• Comparing the size of this grant (12,521 options) and the exercise price ($1.40) to similar companies would require further research into industry benchmarks for director compensation.

Stakeholder Impact

• Shareholders may view the director's acceptance of stock options as a positive sign, aligning their interests with the company's long-term success.

Key Dates